INSUBCONTINENT EXCLUSIVE:
NEW DELHI: Shares of Lupin traded 6.22 per cent up in Tuesday 's trade at 10:33 am (IST)
Around 2104079 shares changed hands on the counter
The stock opened at Rs 690 and touched an intraday high and low of Rs 704.75 and Rs 670.25 , respectively, in the session so far
The stock quoted a 52-week high of Rs 914.9 and a 52-week low of Rs 544.25
Lupin has Launched Mycophenolic Acid Delayed-Release Tablets USP in the US
Its alliance partner Concord Biotech received approval from the US FDA.
Financials Lupin Ltd., incorporated in the year 1983, is a Large Cap
company (having a market cap of Rs 29662.32 Crore) operating in Pharmaceuticals sector
For the quarter ended 31-12-2019, the company reported a Consolidated sales of Rs 3716.09 Crore, down -13.52 % from last quarter Sales of
Rs 4296.90 Crore and down -15.12 % from last year same quarter Sales of Rs 4377.94 Crore Company reported net profit after tax of Rs -841.36
key Products/Revenue Segments include Pharmaceuticals which contributed Rs 10657.32 Crore to Sales Value (93.84 % of Total Sales), Export
Incentives which contributed Rs 250.66 Crore to Sales Value (2.20 % of Total Sales) and Other Operating Revenue which contributed Rs 74.10
Crore to Sales Value (0.65 % of Total Sales)for the year ending 31-Mar-2019
Valuation ratio It quoted a price-to-earnings ratio of -85.2 and price to book value of 2.28